Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma analysis at the eighth year

From June 1976 to June 1981, 86 patients with resectable (Stage I and II) squamous cell lung carcinoma were entered into a randomized controlled study with three arms: Control Group - no treatment postoperatively. Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associat...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Immunotherapy, 1985-12, Vol.20 (3), p.231-235
Main Authors: TAKITA, H, HOLLINSHEAD, A, HART, T. JR, BHAYANA, J, ADLER, R, RAO, U, MOSKOWITZ, R, RAMUNDO, M
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Adult
Aged
Antigens, Neoplasm - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - therapy
Clinical Trials as Topic
Female
Humans
Immunotherapy
Lung Neoplasms - immunology
Lung Neoplasms - therapy
Male
Medical sciences
Middle Aged
Original
Pneumology
Skin Tests
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From June 1976 to June 1981, 86 patients with resectable (Stage I and II) squamous cell lung carcinoma were entered into a randomized controlled study with three arms: Control Group - no treatment postoperatively. Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associated antigen (TAA) emulsified with complete Freund's adjuvant (CFA). Nonspecific Immunotherapy Group - three monthly doses of CFA emulsified in saline. All the patients in the study received skin tests with PPD (5TU) and 100 micrograms of the same TAA used for the immunotherapy at 1, 4, 6, 9, and 12 months postoperatively. Patients in both immunotherapy groups showed a tendency for a better disease-free interval and overall survival compared to those of the control, but these interval and beneficial therapeutic effects were statistically significant only in the Group III patients who had no hilar lymph node metastasis (T1N0 and T2N0). Although Group III was originally designated as a nonspecific immunotherapy group, retrospectively, it should be called a lowdose specific immunotherapy group because these patients actually received a total of 500 micrograms of TAA (as skin tests) and three doses of CFA at separate sites.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF00205582